Testing MSA-01 for multiple system atrophy
Part of Brain & nervous system clinical trials.
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with MSA that is 'clinically established' or 'clinically probable' using standard criteria.
- You can walk on your own or with a walker or cane.
- You are able to come to the study center for appointments.
- You are willing to stop taking CoQ10 supplements during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational imaging agent called SST001, which may help doctors see a protein linked to Parkinson's disease (PD) and multiple system atrophy (MSA) in the body. It will be given to healthy volunteers and patients with PD or MSA to check safety, how it spreads, and how the body handles it.
This study involves people with possible or probable multiple system atrophy (MSA) joining a specialized clinic team and attending visits every 4 months. It’s meant to improve care planning and support by bringing different specialists together.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This early-stage trial tests a new biologic treatment called ALT001 in people with multiple system atrophy-cerebellar type (MSA-C), a rare neurological condition affecting balance and coordination. The study focuses on whether ALT001 is safe and whether it shows early signs of helping slow disease progression.
This study tests a new injection called NouvNeu001 for people with Multiple System Atrophy (MSA). The goal is to see if it can help control symptoms that standard treatments aren't managing well.
Hear when a new Multiple System Atrophy (MSA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.